Mission Focused Team
BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.
The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset, and SBI.
CEO and Board Member
Prior to his role in Biomx, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.
Naomi B. Zak, PhD.
PRESIDENT & COO
Dr. Zak holds a Ph.D. from Harvard Medical School and completed a postdoctoral fellowship at the Weizmann Institute of Science. Dr. Zak has over 15 years of leadership experience in the biotech industry in a range of executive capacities, including: manager of regulatory affairs at Chiasma, a clinical stage company developing oral formulations for medications currently administered parenterally; and director of R&D in both IDgene, a gene discovery company, and CellCure, a clinical stage company developing human embryonic stem cell based therapies. More recently, she served as interim CEO of ProtAb and as CEO of SCTherapeutics. Dr. Zak has led company launching activities, target indication assessment, establishment of research platforms, and product development activities.
Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.
Before joining Biomx, Ms. Fattal served as an executive officer, CFO (May 2013 to January 2016), and vice president of finance (October 2012 to May 2013) of Evogene Ltd. Previously, Ms. Fattal was the CFO and executive vice president of Transpharma Medical Ltd. Prior to joining TransPharma, she was the director of finance (2001 to 2004) and the corporate controller (1998 to 2000) at ECtel Ltd. (Nasdaq: ECTX). Ms. Fattal has extensive experience working in the capital markets, including IPO, PIPE, and M&A transactions, as well as managing financial, operational, and business activities. Ms. Fattal holds a B.A. in Accounting and Economics with honors and an M.B.A., both from Tel Aviv University.
Dr. Sailaja Puttagunta M.D.
Dr. Sailaja Puttagunta, M.D., was most recently Vice President, Development at Iterum Therapeutics, a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan from early 2015 and was the VP of Development and Medical Affairs at Durata Therapeutics, Inc. prior to its acquisition by Actavis plc. From 2006 to 2012, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta has 20 years of clinical, academic and research experience in medicine and in the sub-specialty of infectious diseases. She graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an MS in Biochemistry from the New York University School of Medicine.
BOARD OF DIRECTORS
Rob Woodman, Ph.D
Dr. Rob Woodman joined TVI in March 2018 as Senior Partner, and is based in London, UK. Prior to joining TVI, Rob was Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London. He has led the formation of and fundraising for a number of UK biotech companies, such as Mission Therapeutics, Crescendo Biologics, Storm Therapeutics, and Enterprise Therapeutics. Rob joined Touchstone Innovations in 2012 and was previously a Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. While at Sofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience also includes technology transfer with Cancer Research Technology (CRUK) and pharmaceutical consultancy with IMS Health. Rob holds an MSc in Biochemistry from the University of Oxford and a Ph.D. in Oncology from the University of Cambridge.
Erez Chimovits is a senior managing director at Orbimed Healthcare Fund Management. Mr. Chimovits has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, Mr. Chimovits was the CEO of NasVax (TASE:NSVX), which acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Mr. Chimovits spent more than seven years with Compugen (Nasdaq:CGEN), as president of Compugen USA Inc., and as executive vice president of commercial operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions with companies including J&J, Novartis, Teva, Abbott, and Medarex. Mr. Chimovits earned his M.B.A., M.Sc. in Microbiology, and B.Sc. from Tel Aviv University.
Zeev Zehavi is vice president of venture investments for Johnson & Johnson Innovation – JJDC, Inc., which he joined in 1999. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as president of the bulk chemical business in North America. He returned to Israel as president of Clal Pharmaceutical Industries (CPI) for four years before starting his own medical device and pharmaceutical start-up consulting business, Pharma Zee, Ltd., where he initiated contacts with various Johnson & Johnson companies. Mr. Zehavi holds a B.Sc. from the Hebrew University of Jerusalem and an M.B.A. in Marketing and Finance from Tel Aviv University.
Henk Brulleman started his career at Royal Dutch Shell and rose to the position of deputy chief investment officer of their pension fund. He subsequently became a partner at Numeric Investors LLC, a Boston-based quantitative equity management firm, where he co-managed portfolios with a combined value of $3 billion and also handled client relations, marketing, and modeling. After retiring from Numeric, he built a portfolio of several equity and convertible debt stakes, predominantly in the field of life sciences, pharmaceuticals, and medical technology. He recently joined Wolkers & Co, a fiduciary asset manager providing multi-family office services, as a partner. Henk holds the equivalent of a M.Sc in Business Economics from the Free University in Amsterdam and is a CFA Charterholder.
Eric de La Fortelle, Ph.D
Eric de La Fortelle is Venture Partner with Seventure Partners, which he joined in 2014. Prior to this, Dr. de La Fortelle was CEO at Swiss antibody biotech Delenex Pharmaceuticals, and also spent 6 years as Global Head, External Research and Technologies at Roche headquarters in Basel. He is a scientist by training, with an engineering degree from Ecole Centrale de Paris, a PhD in biophysics and research contributions in the field of protein crystallography.
Yaron Breski is a Founding Partner at RMGP Biopharma Investment Fund and Managing Director at RM Global. Mr. Breski holds over 14 years of experience in healthcare, finance, and business development, and is focused on developing and executing novel models to financing life science innovation. Previously, Mr. Breski served as a senior executive of business development at Rosetta Genomics, a biotech company focusing on cancer diagnostics. Before that Mr. Breski was part of the US Strategic Planning group at Novartis, and before with Booz Allen’s Healthcare group in New York. Mr. Breski holds a B.Sc. in Biology, Magna Cum Laude, research track for honors students from the Tel Aviv University; and an M.B.A from The Wharton School, University of Pennsylvania.
Prof. Rotem Sorek
Prof. Sorek leads the Microbial Genomics group in the Department of Molecular Genetics at the Weizmann Institute of Science. He is a world leader in phage genomics and CRISPR research,
and also develops techniques for high resolution understanding of microbial transcriptomics and metatranscriptomics. Prof. Sorek holds a Ph.D. in Human Genomics from Tel Aviv University, and in his postdoc, studied microbial metagenomics at the Lawrence Berkeley National Laboratory. Prior to joining the Weizmann Institute, Prof. Sorek headed the Genomics Research Group at Compugen (Nasdaq:CGEN). Prof. Sorek is also an author of numerous scientific publications in top-tier journals, and an inventor of more than 35 patents. He has received multiple awards, including the 2012 Rubinowitz-Grossman Prize in Microbiology, the 2013 Teva Founders Award for young scientists, and the 2014 FEBS Anniversary Prize. In 2015, Prof. Sorek was elected as a member of the European Academy of Microbiology.
Prof. Eran Elinav
Prof. Elinav is a senior scientist leading a research group in the Immunology Department at the Weizmann Institute of Science. Prof. Elinav has over 110 published articles and received several awards for his work, including the 2013 Alon Prize and the 2015 Rappaport Prize for outstanding biomedical research. Before joining the Weizmann Institute, Prof. Elinav held an independent research position at the Institute for Gastroenterology and Liver Disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his M.D. at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by internship, residency, clinical, and research positions at the Tel Aviv Medical Center Gastroenterology Institute. Prof. Elinav also has a Ph.D. in immunology from the Weizmann Institute of Science and served in a postdoctoral fellowship at the Yale University School of Medicine.
Prof. Timothy K. Lu
Prof. Lu is an associate professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Prof. Lu graduated with an S.B. and M.Eng. from MIT, and an M.D./Ph.D. from the Harvard-MIT Health Sciences and Technology program. He is also a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies that develop innovative diagnostic and therapeutic technologies for human health. Prof. Lu is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
Prof. Richard A. Flavell, Ph.D
Dr. Flavell is a Sterling Professor of Immunobiology at Yale University and an Investigator at the Howard Hughes Medical Institute. He received his B.Sc. and Ph.D. from the University of Hull and performed postdoctoral work with Piet Borst and Charles Weissmann. Dr. Flavell was also first assistant professor (equivalent) at the University of Amsterdam (1974-79); head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and president and chief scientific officer of Biogen Research Corporation (1982-88). Dr. Flavell is a fellow of the Royal Society and a member of EMBO, the National Academy of Sciences, and the National Academy of Medicine. Dr. Flavell was also the founding chairman of Yale’s Department of Immunobiology, has published more than 1,000 peer reviewed papers, and is one of the world’s most cited immunologists.
Michael Koeris, Ph.D
Dr. Koeris is the co-founder and CEO of Sample6, a leading food-safety diagnostics provider using engineered bacteriophages to deliver the world’s first on-site, in-shift bacterial pathogen detection system. Dr. Koeris ideated and instantiated the company’s synthetic biology engineering platform, and protected product lines and manufacturing processes with 15+ patents and application portfolios. The company’s technology originated in Jim Collins’ Synthetic Biology laboratory at MIT and was expanded to include key new inventions enabling a first-in-class phage genome engineering patent for bacteriophages. This novel approach, using yeast-based recombineering, allows the assembly of modified genomes and the addition of modifications post-assembly in yeast. Dr. Koeris also worked at McKinsey & Company and Flagship Ventures, and in Jim Collins’ lab, focusing on bacterial resistance mechanisms, for his Ph.D. He remains a visiting scholar at MIT.
LEARN MORE ABOUT BIOMX MISSION FOR HEALTH